GR20010300018T1 - INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS - Google Patents

INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS

Info

Publication number
GR20010300018T1
GR20010300018T1 GR20010300018T GR20010300018T GR20010300018T1 GR 20010300018 T1 GR20010300018 T1 GR 20010300018T1 GR 20010300018 T GR20010300018 T GR 20010300018T GR 20010300018 T GR20010300018 T GR 20010300018T GR 20010300018 T1 GR20010300018 T1 GR 20010300018T1
Authority
GR
Greece
Prior art keywords
aryl
inhibition
kinase activity
substituted heterocyclic
heteroaryl substituted
Prior art date
Application number
GR20010300018T
Other languages
Greek (el)
English (en)
Inventor
Jacques Dumas
Uday Khire
Timothy Bruno Lowinger
Bernd Riedl
William J Scott
Roger A Smith
Jill E Wood
Holia Hatoum-Mokdad
Jeffrey Johnson
Aniko Redman
Robert Sibley
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of GR20010300018T1 publication Critical patent/GR20010300018T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyridine Compounds (AREA)
GR20010300018T 1997-12-22 2001-05-31 INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS GR20010300018T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99575197A 1997-12-22 1997-12-22
PCT/US1998/026079 WO1999032110A1 (en) 1997-12-22 1998-12-22 INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS

Publications (1)

Publication Number Publication Date
GR20010300018T1 true GR20010300018T1 (en) 2001-05-31

Family

ID=25542169

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20010300018T GR20010300018T1 (en) 1997-12-22 2001-05-31 INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS

Country Status (13)

Country Link
EP (1) EP1043995B9 (enExample)
JP (1) JP2001526222A (enExample)
AT (1) ATE346600T1 (enExample)
AU (1) AU762077B2 (enExample)
CA (1) CA2315647C (enExample)
CY (1) CY1107995T1 (enExample)
DE (2) DE69836563T2 (enExample)
DK (1) DK1043995T3 (enExample)
ES (1) ES2155817T3 (enExample)
GR (1) GR20010300018T1 (enExample)
IL (2) IL136768A0 (enExample)
PT (1) PT1043995E (enExample)
WO (1) WO1999032110A1 (enExample)

Families Citing this family (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
EP1473292A1 (en) * 1997-11-03 2004-11-03 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
JP2001521934A (ja) * 1997-11-03 2001-11-13 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 抗炎症薬としての芳香族ヘテロ環式化合物
RU2265597C2 (ru) * 1997-12-22 2005-12-10 Байер Копэрейшн Арил- и гетероарилзамещенные гетероциклические производные мочевины, способ ингибирования киназы raf и фармацевтическая композиция
CA2315720A1 (en) * 1997-12-22 1999-07-01 Bayer Corporation Inhibition of p38 kinase activity using substituted heterocyclic ureas
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
WO2000025791A1 (en) 1998-11-04 2000-05-11 Smithkline Beecham Corporation Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines
EP1140840B1 (en) * 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
RU2319693C9 (ru) 1999-01-13 2008-08-20 Байер Копэрейшн Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты)
DK1690853T3 (da) * 1999-01-13 2010-06-07 Bayer Healthcare Llc Omega-carboxyaryl-substituerede diphenylurinstoffer til anvendelse som raf-kinaseinhibitorer
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ATE538794T1 (de) 1999-01-13 2012-01-15 Bayer Healthcare Llc Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
UA73492C2 (en) * 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
WO2000050425A1 (en) 1999-02-22 2000-08-31 Boehringer Ingelheim Pharmaceuticals, Inc. Polycyclo heterocyclic derivatives as antiinflammatory agents
EP1163236B1 (en) 1999-03-12 2005-11-09 Boehringer Ingelheim Pharmaceuticals Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
ID30176A (id) 1999-03-12 2001-11-08 Boehringer Ingelheim Pharma Senyawa-senyawa yang bermanfaat sebagai zat anti-inflamasi
EP1200411B1 (en) 1999-07-09 2005-12-14 Boehringer Ingelheim Pharmaceuticals Inc. Process for synthesis of heteroaryl-substituted urea compounds
CA2389360C (en) 1999-11-16 2008-06-03 Steffen Breitfelder Urea derivatives as anti-inflammatory agents
AU1781601A (en) 1999-11-23 2001-06-04 Smithkline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
AU1782301A (en) 1999-11-23 2001-06-04 Smithkline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p39 kinase inhibitors
DE60020595T2 (de) 1999-11-23 2006-03-16 Smithkline Beecham Corp. 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
US6525046B1 (en) 2000-01-18 2003-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as antiinflammatory agents
US6608052B2 (en) 2000-02-16 2003-08-19 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
JP2003528084A (ja) * 2000-03-22 2003-09-24 バーテックス ファーマシューティカルズ インコーポレイテッド ｐ３８のインヒビター
US6645990B2 (en) 2000-08-15 2003-11-11 Amgen Inc. Thiazolyl urea compounds and methods of uses
EP1506962B1 (en) 2000-10-20 2008-07-02 Eisai R&D Management Co., Ltd. Nitrogen-containing aromatic heterocycles
JP2004517080A (ja) 2000-11-29 2004-06-10 グラクソ グループ リミテッド Ｔｉｅ−２および／またはｖｅｇｆｒ−２の阻害剤として有用なベンゾイミダゾール誘導体
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
DE10109204A1 (de) * 2001-02-26 2002-09-19 4Sc Ag Verbindungen zur Behandlung von Protozoen-Erkrankungen
EP1395548A1 (en) 2001-02-26 2004-03-10 4Sc Ag Derivatives of diphenylurea, diphenyloxalic acid diamide and diphenylsulfuric acid diamide and their use as medicaments
US7371763B2 (en) 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
JP2004530690A (ja) 2001-05-16 2004-10-07 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 抗炎症性薬剤として有用なジアリールウレア誘導体
WO2002096876A1 (en) 2001-05-25 2002-12-05 Boehringer Ingelheim Pharmaceuticals, Inc. Carbamate and oxamide compounds as inhibitors of cytokine production
ATE338035T1 (de) 2001-06-05 2006-09-15 Boehringer Ingelheim Pharma 1,4-disubstituierte benzokondensierte cycloalkyl harnstoffverbindungen
ATE360417T1 (de) 2001-07-11 2007-05-15 Boehringer Ingelheim Pharma Methode zur behandlung von zytokinvermittelten erkrankungen
US6825184B2 (en) 2001-10-18 2004-11-30 Boehringer Ingelheim Pharmaceuticals, Inc. 1,4-Disubstituted benzo-fused urea compounds
DE10203086A1 (de) * 2002-01-28 2003-07-31 Bayer Ag 5-Ring Heterozyklen
US20040023961A1 (en) * 2002-02-11 2004-02-05 Bayer Corporation Aryl ureas with raf kinase and angiogenisis inhibiting activity
SI1580188T1 (sl) 2002-02-11 2012-02-29 Bayer Healthcare Llc Aril sečnine kot kinazni inhibitorji
SI1478358T1 (sl) 2002-02-11 2013-09-30 Bayer Healthcare Llc Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
WO2003072569A1 (en) 2002-02-25 2003-09-04 Boehringer Ingelheim Pharmaceuticals, Inc. 1,4-disubstituted benzofused cycloalkyl urea compounds useful in treating cytokine mediated diseases
ATE349210T1 (de) 2002-07-09 2007-01-15 Boehringer Ingelheim Pharma Pharazeutische zusammensetzungen aus anticholinergica und p38 kinase hemmern zur behandlung von erkrankungen der atemwege
AU2003257991A1 (en) 2002-08-08 2004-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Fluorinated phenyl-naphthalenyl-urea compounds as inhibitors of cytokines involved in inflammatory processes
WO2004019873A2 (en) 2002-08-29 2004-03-11 Scios Inc. Methods of promoting osteogenesis
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
EP1608639A2 (en) 2003-02-28 2005-12-28 Bayer Pharmaceuticals Corporation Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders
BRPI0408815A (pt) * 2003-03-28 2006-04-04 Pharmacia & Upjohn Co Llc moduladores alostéricos positivos do receptor nicotìnico da acetilcolina
GB0320244D0 (en) 2003-05-06 2003-10-01 Aventis Pharma Inc Pyrazoles as inhibitors of tumour necrosis factor
EP1626714B1 (en) 2003-05-20 2007-07-04 Bayer Pharmaceuticals Corporation Diaryl ureas for diseases mediated by pdgfr
EP1663978B1 (en) 2003-07-23 2007-11-28 Bayer Pharmaceuticals Corporation Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
CN102060806A (zh) 2003-09-11 2011-05-18 iTherX药品公司 细胞因子抑制剂
US7244441B2 (en) 2003-09-25 2007-07-17 Scios, Inc. Stents and intra-luminal prostheses containing map kinase inhibitors
JP4303726B2 (ja) 2003-11-11 2009-07-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 ウレア誘導体およびその製造方法
TW200530236A (en) 2004-02-23 2005-09-16 Chugai Pharmaceutical Co Ltd Heteroaryl phenylurea
US20060211752A1 (en) 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
WO2005110994A2 (en) 2004-04-30 2005-11-24 Bayer Pharmaceuticals Corporation Substituted pyrazolyl urea derivatives useful in the treatment of cancer
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
US8969379B2 (en) 2004-09-17 2015-03-03 Eisai R&D Management Co., Ltd. Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide
US7741479B2 (en) 2004-12-07 2010-06-22 Locus Pharmaceuticals, Inc. Urea inhibitors of MAP kinases
US7612200B2 (en) 2004-12-07 2009-11-03 Locus Pharmaceuticals, Inc. Inhibitors of protein kinases
JP2008524213A (ja) * 2004-12-20 2008-07-10 アストラゼネカ・アクチエボラーグ 新規なピラゾール誘導体及びニコチン性アセチルコリン受容体のモジュレーターとしてのそれらの使用
AU2005321946B2 (en) * 2004-12-23 2012-08-16 Deciphera Pharmaceuticals, Llc Enzyme modulators and treatments
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
EP1676574A3 (en) 2004-12-30 2006-07-26 Johnson & Johnson Vision Care, Inc. Methods for promoting survival of transplanted tissues and cells
GB0500435D0 (en) * 2005-01-10 2005-02-16 Novartis Ag Organic compounds
CA2601955C (en) 2005-03-07 2012-07-10 Bayer Healthcare Ag Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
DE102005015253A1 (de) 2005-04-04 2006-10-05 Merck Patent Gmbh Pyrazolderivate
WO2007015578A1 (ja) 2005-08-02 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を検定する方法
DE102005037499A1 (de) * 2005-08-09 2007-02-15 Merck Patent Gmbh Pyrazolderivate
PE20070795A1 (es) * 2005-10-28 2007-08-24 Lilly Co Eli Compuestos pirazol-urea-heterociclicos como inhibidores de cinasa
JP2009513649A (ja) * 2005-10-28 2009-04-02 イーライ リリー アンド カンパニー キナーゼ阻害剤
EP1973897B1 (en) * 2005-12-21 2014-05-21 Bayer Intellectual Property GmbH Substituted pyrimidine derivatives useful in the treatment of cancer and other disorders
CA2652442C (en) 2006-05-18 2014-12-09 Eisai R & D Management Co., Ltd. Antitumor agent for thyroid cancer
WO2007139930A2 (en) 2006-05-26 2007-12-06 Bayer Healthcare Llc Drug combinations with substituted diaryl ureas for the treatment of cancer
EP2065372B1 (en) 2006-08-28 2012-11-28 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
WO2008079972A2 (en) 2006-12-20 2008-07-03 Bayer Healthcare Llc 4-{4- [ ({3-tert-butyl-1- [3- (hydroxymethyl) phenyl] - 1h- pyrazol- 5 -yl } carbamoyl) -amin o] -3-chlorophenoxy} -n-methylpyridine-2-carboxamide as an inhibitor of the vegfr kinase for the treatment of cancer
US8962655B2 (en) 2007-01-29 2015-02-24 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated gastric cancer
CA2682162C (en) 2007-04-02 2016-05-10 Renovis, Inc. Pyrid-2-yl fused heterocyclic compounds, and compositions and uses thereof
BRPI0807717A2 (pt) 2007-04-20 2014-05-20 Deciphera Pharmaceuticals Llc Inibidores de quinase úteis para o tratamento de doenças mieloproliferativas e outras doenças proliferativas.
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
WO2009035949A2 (en) * 2007-09-13 2009-03-19 Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors
CN101848895B (zh) 2007-11-09 2013-10-23 卫材R&D管理有限公司 血管新生抑制物质和抗肿瘤性铂络合物的组合使用
PE20110598A1 (es) 2008-10-02 2011-08-31 Respivert Ltd Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38
GB0818033D0 (en) 2008-10-02 2008-11-05 Respivert Ltd Novel compound
MX2011006220A (es) 2008-12-11 2011-06-28 Respivert Ltd Inhibidores de la proteina cinasa activada por el mitogeno p38.
EP3312269A1 (en) 2008-12-17 2018-04-25 The Scripps Research Institute Generation and maintenance of stem cells
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
US9260410B2 (en) 2010-04-08 2016-02-16 Respivert Ltd. P38 MAP kinase inhibitors
ES2573515T3 (es) 2010-06-25 2016-06-08 Eisai R&D Management Co., Ltd. Agente antitumoral que emplea compuestos con efecto inhibitorio de cinasas combinados
CA2805874A1 (en) 2010-07-19 2012-01-26 Bayer Healthcare Llc Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
MX2013009931A (es) 2011-04-18 2013-10-01 Eisai R&D Man Co Ltd Agentes terapeuticos contra tumores.
UA114711C2 (uk) * 2011-05-13 2017-07-25 Еррей Біофарма Інк. Сполуки піролідинілсечовини й піролідинілтіосечовини як інгібітори кінази trka
EP2714937B1 (en) 2011-06-03 2018-11-14 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
EP2763984B1 (en) 2011-10-03 2016-04-20 Respivert Limited 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 map kinase inhibitors
EP2578582A1 (en) 2011-10-03 2013-04-10 Respivert Limited 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors
WO2013096637A1 (en) * 2011-12-23 2013-06-27 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
JP6218229B2 (ja) 2011-12-28 2017-10-25 京都府公立大学法人 角膜内皮細胞の培養正常化
WO2013162027A1 (ja) 2012-04-27 2013-10-31 学校法人 慶應義塾 神経分化促進剤
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
GB201214750D0 (en) 2012-08-17 2012-10-03 Respivert Ltd Compounds
GB201215357D0 (en) 2012-08-29 2012-10-10 Respivert Ltd Compounds
US9809578B2 (en) 2012-11-13 2017-11-07 Array Biopharma Inc. Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trkA kinase inhibitors
WO2014078378A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9790210B2 (en) 2012-11-13 2017-10-17 Array Biopharma Inc. N-(monocyclic aryl),N'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
HRP20161613T1 (hr) 2012-11-13 2017-01-13 Array Biopharma, Inc. Tvari bicikličke ureje, tioureje, gvanidina i cijanogvanidina korisne za liječenje boli
US9822118B2 (en) 2012-11-13 2017-11-21 Array Biopharma Inc. Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078328A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078331A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
EP2922844B1 (en) 2012-11-13 2018-01-10 Array Biopharma, Inc. N-pyrrolidinyl, n'-pyrazolyl- urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9981959B2 (en) 2012-11-13 2018-05-29 Array Biopharma Inc. Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
US9790178B2 (en) 2012-11-13 2017-10-17 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
MX2015004979A (es) 2012-12-21 2015-07-17 Eisai R&D Man Co Ltd Forma amorfa de derivado de quinolina y metodo para su produccion.
US20160016934A1 (en) 2013-03-14 2016-01-21 Respivert Limited Kinase inhibitors
NZ714049A (en) 2013-05-14 2020-05-29 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
US9750723B2 (en) 2013-10-31 2017-09-05 Ohio University Prevention and treatment of non-alcoholic fatty liver disease
EP3069732B1 (en) 2013-11-14 2023-07-12 The Doshisha Drug for treating corneal endothelium by promoting cell proliferation or inhibiting cell damage
TWI664967B (zh) 2014-02-14 2019-07-11 英商瑞斯比維特有限公司 新穎化合物（一）
RU2719489C2 (ru) 2014-05-15 2020-04-17 Эррэй Биофарма Инк. 1-((3S,4R)-4-(3-ФТОРФЕНИЛ)-1-(2-МЕТОКСИЭТИЛ)ПИРРОЛИДИН-3-ИЛ)-3-(4-МЕТИЛ-3-(2-МЕТИЛПИРИМИДИН-5-ИЛ)-1-ФЕНИЛ-1Н-ПИРАЗОЛ-5-ИЛ)МОЧЕВИНА В КАЧЕСТВЕ ИНГИБИТОРА TrkA КИНАЗЫ
WO2016010610A2 (en) 2014-07-18 2016-01-21 Ohio University Imidazole and thiazole compositions for modifying biological signaling
CN113683564A (zh) 2014-08-28 2021-11-23 卫材R&D管理有限公司 高纯度喹啉衍生物及其生产方法
LT3263106T (lt) 2015-02-25 2024-01-10 Eisai R&D Management Co., Ltd. Chinolino darinių kartumo sumažinimo būdas
CA2978226C (en) 2015-03-04 2025-02-18 Eisai R&D Management Co., Ltd. COMBINATION OF A PD-1 ANTAGONIST AND A VEGFR/FGFR/RET TYROSINE KINASE INHIBITOR TO TREAT CANCER
CN107801379B (zh) 2015-06-16 2021-05-25 卫材R&D管理有限公司 抗癌剂
RU2718048C2 (ru) 2015-08-20 2020-03-30 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое терапевтическое средство
WO2018147275A1 (ja) 2017-02-08 2018-08-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療用医薬組成物
RU2019134940A (ru) 2017-05-16 2021-06-16 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Лечение гепатоцеллюлярной карциномы
BR112020015581A2 (pt) 2018-01-31 2021-02-02 Deciphera Pharmaceuticals, Llc terapia de combinação para o tratamento de tumores estromais gastrointestinais
EP3746060A1 (en) 2018-01-31 2020-12-09 Deciphera Pharmaceuticals, LLC Combination therapy for the treatment of mastocytosis
RS63124B1 (sr) 2018-03-08 2022-05-31 Incyte Corp Aminopirazin diol jedinjenja kao pi3k-y inhibitori
EP3773579A4 (en) 2018-03-26 2022-03-09 Clear Creek Bio, Inc. COMPOSITIONS AND METHODS FOR INHIBITING DIHYDROOROTATE DEHYDROGENASE
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
KR20220045189A (ko) 2019-08-12 2022-04-12 데시페라 파마슈티칼스, 엘엘씨. 위장관 기질 종양을 치료하는 방법
WO2021030405A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
SMT202300467T1 (it) 2019-12-30 2024-01-10 Deciphera Pharmaceuticals Llc Formulazioni di inibitori di chinasi amorfi e loro procedimenti d’uso
CN118948773A (zh) 2019-12-30 2024-11-15 德西费拉制药有限责任公司 1-(4溴-5-(1乙基-7-(甲氨基)-2侧氧基-1,2-二氢-1,6-萘啶-3基)-2氟苯基)-3-苯基脲的组合物
US20210290651A1 (en) 2020-03-20 2021-09-23 Clear Creek Bio, Inc. Methods of treating viral infections using inhibitors of nucleotide synthesis pathways
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0056465B1 (en) * 1980-12-23 1985-09-04 The Wellcome Foundation Limited Pyrazoline derivatives, processes for their preparation and pharmaceutical formulations containing them
GB8417453D0 (en) * 1984-07-09 1984-08-15 Fujisawa Pharmaceutical Co Semicarbazide derivatives
EP0525197B1 (en) * 1991-01-21 1997-08-27 Shionogi Seiyaku Kabushiki Kaisha 3-benzylidene-1-carbamoyl-2-pyrrolidone analogs
US5162360A (en) * 1991-06-24 1992-11-10 Warner-Lambert Company 2-heteroatom containing urea and thiourea ACAT inhibitors
CA2171982C (en) * 1993-09-17 2000-02-01 John Cheung-Lun Lee Drug binding protein
US5559137A (en) * 1994-05-16 1996-09-24 Smithkline Beecham Corp. Compounds
US5773459A (en) * 1995-06-07 1998-06-30 Sugen, Inc. Urea- and thiourea-type compounds
PL192628B1 (pl) * 1996-04-23 2006-11-30 Vertex Pharma Pochodne mocznika, kompozycje farmaceutyczne i zastosowanie związku i kompozycji
JP2001521934A (ja) * 1997-11-03 2001-11-13 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 抗炎症薬としての芳香族ヘテロ環式化合物
RU2265597C2 (ru) * 1997-12-22 2005-12-10 Байер Копэрейшн Арил- и гетероарилзамещенные гетероциклические производные мочевины, способ ингибирования киназы raf и фармацевтическая композиция

Also Published As

Publication number Publication date
ES2155817T3 (es) 2007-06-16
WO1999032110A1 (en) 1999-07-01
IL136768A0 (en) 2001-06-14
DE1043995T1 (de) 2001-06-07
DE69836563T2 (de) 2007-05-16
HK1031832A1 (en) 2001-06-29
CY1107995T1 (el) 2013-09-04
EP1043995B1 (en) 2006-11-29
PT1043995E (pt) 2007-01-31
ES2155817T1 (es) 2001-06-01
DK1043995T3 (da) 2007-03-05
AU1997099A (en) 1999-07-12
CA2315647C (en) 2009-09-29
CA2315647A1 (en) 1999-07-01
EP1043995B9 (en) 2008-10-08
AU762077B2 (en) 2003-06-19
IL136768A (en) 2006-10-31
ATE346600T1 (de) 2006-12-15
EP1043995A4 (en) 2003-05-07
EP1043995A1 (en) 2000-10-18
DE69836563D1 (de) 2007-01-11
JP2001526222A (ja) 2001-12-18

Similar Documents

Publication Publication Date Title
GR20010300018T1 (en) INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS
IL136738A0 (en) Inhibition of p38 kinase activity using substituted heterocyclic ureas
AU7585498A (en) Inhibition of p38 kinase activity by aryl ureas
IL136737A0 (en) Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
BR9811956B1 (pt) naftiridinonas e composição farmacêutica compreendendo as mesmas.
IL144144A0 (en) Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
AP2000001996A0 (en) Heterocyclic inhibitors of P38.
BG104599A (en) Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
IL125282A (en) Substituted imidazole compounds, process for their preparation, pharmaceutical compositions containing them and use thereof in the preparation of medicaments for treating cytokine mediated diseases
TR200100918T2 (tr) Aril ve heteroaril sübstitüentli üreler kullanılarak RAF kinazın inhibe edilmesi
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
AU8377698A (en) Inhibitors of p38
AP9901435A0 (en) Bicycle heteroaromatic compounds as protein tyrosine kinase inhibitors.
NZ508268A (en) Bicyclic pyrimidines and bicyclic 3,4- dihydropyrimidines as inhibitors of cellular proliferation
UA66865C2 (uk) Інденопіролокарбазоли, фармацевтична композиція, спосіб інгібування кіназної активності та спосіб лікування (варіанти)
ID19142A (id) Inhibitor-inhibitor sikloalkil pada protein farnesiltransferase
BG105763A (en) Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
GEP20012440B (en) Biphenylsulfonamide Matrix Metalloproteinase Inhibitors
MY129421A (en) INHIBITORS OF p38